IART

AI Memo

Integra LifeSciences

As of 2026-10-11/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

October 21 results test the revised outlook • 2026-10-21

Base target: $15 / p=45% prob

Biggest risk

The Cincinnati disruption, reduced outlook and higher refinancing cost compound execution risk. The October results must establish whether preliminary figures and recovery assumptions hold; no verified post-update analyst estimate or target revisions were supplied. [#SEC-8K-2026-10-02] [#8-K-2026-10-09]

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Cash generation and manufacturing recovery could support deleveraging and renewed product availability. Integra maintained an approximately $190 million–$200 million 2026 operating-cash-flow expectation despite lowering revenue and adjusted EPS guidance. [#SEC-8K-2026-10-02]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-11

Base target

$15

p=45%

Bull target

$19

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Higher refinancing cost
Cincinnati manufacturing recovery
Cash generation and manufacturing recovery could support deleveraging and renewed product availability.

BearKey bullets

Further Cincinnati restoration delays or larger-than-estimated Q4 supply losses.
[#SEC-8K-2026-10-02]
Insurance recoveries may differ from Integra’s expectation of mitigating a substantial portion of disruption-related earnings impact.

WatchKey bullets

October 21 results test the revised outlook

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $15 (p=45%)

Target spread vs base: +27% / -40%

Scenario probabilities

Bull Target: $19 (p=25%)Base Target: $15 (p=45%)Bear Target: $9 (p=30%)

Commentary

The October 2 guidance cut and October 9 refinancing terms weigh on news tone, while the October 9 adjusted-close anchor is $13.44. The packet does not establish a verified post-refinancing price reaction or post-update analyst revisions. Social coverage is insufficient; zero-valued social, options, short-interest and employee fields indicate unavailable observations, not neutral readings. [#SEC-8K-2026-10-02] [#8-K-2026-10-09]

As of 2026-10-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Higher refinancing cost
Cincinnati manufacturing recovery

Scenarios

Bull Target (Scenario probability)

$19 / p=25% prob

Base Target (Scenario probability)

$15 / p=45% prob

Bear Target (Scenario probability)

$9 / p=30% prob

Analysis 2026-10-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.50

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-21
October 21 results test the revised outlook
Integra scheduled its third-quarter release and call for October 21. Preliminary, unaudited Q3 revenue is $410 million–$412 million and adjusted EPS is $0.55–$0.59. The company cut 2026 revenue guidance to $1.634 billion–$1.654 billion and adjusted EPS guidance to $2.30–$2.40; final results and updated recovery assumptions are the near-term test. [#PR-EARNINGS-2026-10-06] [#SEC-8K-2026-10-02]
Prob 90.00% • Move -5.00% • Priced-in 65.00%
EVENT2026-12-31
Planned SurgiMend relaunch
Integra reported that production had begun at Braintree and maintained a planned fourth-quarter SurgiMend relaunch. Completion and reliable supply remain unconfirmed execution tests. [#SEC-8K-2026-07-29]
Prob 60.00% • Move 8.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Higher refinancing cost
2026-12-31
An October 9 filing announced pricing of $450 million of 9.500% senior secured notes due 2033. Integra expects its refinancing plan to raise its effective interest rate near the high end of the previously communicated 100–200-basis-point range, increasing pressure on future earnings and cash available for deleveraging. [#8-K-2026-10-09]
Prob 80% • Move -4% • Priced-in 50%

Long-term Catalysts

Months to a year

Cincinnati manufacturing recovery
2027-06-30
Integra estimates flood-related supply disruption reduced Q3 revenue by about $7 million and will reduce Q4 revenue by $15 million–$20 million. It expects full manufacturing operations during Q2 2027; delay or incomplete insurance recovery would weaken the recovery case. [#SEC-8K-2026-10-02]
Prob 55% • Move 12% • Priced-in 25%

Risks

Further Cincinnati restoration delays or larger-than-estimated Q4 supply losses. [#SEC-8K-2026-10-02]
Insurance recoveries may differ from Integra’s expectation of mitigating a substantial portion of disruption-related earnings impact. [#SEC-8K-2026-10-02]
Preliminary Q3 figures remain subject to closing procedures, and the revised full-year outlook also reflects changed assumptions for the broader business. [#SEC-8K-2026-10-02]
Refinancing raises the expected effective interest rate near the high end of the previously indicated 100–200-basis-point range. [#8-K-2026-10-09]
The planned SurgiMend relaunch and Braintree production ramp remain execution-dependent. [#SEC-8K-2026-07-29]

Peers

Symbol	Summary
AORT	A similarly sized medical-device candidate in the packet, but its cardiovascular focus differs from Integra’s neurosurgery and tissue-reconstruction portfolio.
TFX	A surgical and hospital-device operating reference from the prior baseline, but product mix and scale differ; not a direct valuation multiple.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-11

Loading AI feed…

Symbol

Summary

AORT

A similarly sized medical-device candidate in the packet, but its cardiovascular focus differs from Integra’s neurosurgery and tissue-reconstruction portfolio.

TFX

A surgical and hospital-device operating reference from the prior baseline, but product mix and scale differ; not a direct valuation multiple.